Education
About Us
Working with TipRanks
Follow Us
Evgen Pharma PLC (GB:TCF)
LSE:TCF
TCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.20p - 1.25p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.14M
Market Cap
£5.16M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Dec 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume1,697,985
30 Day Avg. Volume1,141,423
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evgen Pharma News
TCF FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest share price was 0.20p and its highest was 1.25p in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is £5.16M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Dec 18, 2025 which is in 137 days.
How were Evgen Pharma PLC’s earnings last quarter?
Currently, no data Available
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in GB:TCF
Company Description
Evgen Pharma PLC
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Evgen Pharma (TCF) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
HemoGenyx Pharmaceuticals Plc
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Ownership Overview
1.83% Insiders
―
Mutual Funds
― Other Institutional Investors
98.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---